The role of complement in invasive fungal infections

Mycoses

Volumn 47, Issue 3-4, 2004, Pages 93-103

  Speth, Cornelia ^a,c   Rambach, Günter ^b   Lass Flörl, Cornelia ^a   Dierich, Manfred P ^a   Würzner, Reinhard ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Aspergillosis; Blastomycosis; Candidosis; Complement; Cryptococcosis; Histoplasmosis; Paracoccidioidomycosis

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; COMPLEMENT RECEPTOR;

ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; CANDIDA; CANDIDIASIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HISTOPLASMOSIS; HUMAN; IMMUNE SYSTEM; IMMUNITY; MYCOSIS; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; SOUTH AMERICAN BLASTOMYCOSIS;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, NATURAL; IMMUNOCOMPROMISED HOST; MITOSPORIC FUNGI; MYCOSES;

AJELLOMYCES DERMATITIDIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; BLASTOMYCES; CANDIDA; FILOBASIDIELLA NEOFORMANS; FUNGI; PARACOCCIDIOIDES BRASILIENSIS;

EID: 2342616160     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2004.00979.x     Document Type: Review

References (99)

1. Jarvis MR. Epidemiology of nosokomial fungal infections, with emphasis on Candida species. Clin Inf Dis 1995; 20: 1526-30.
2. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002; 81: 233-43.
3. Speth C, Würzner R, Stoiber H, Dierich MP. The complement system: pathophysiology and clinical relevance. Wien Klin Wochenschr 1999; 111/10: 378-91.
4. Prodinger WM, Würzner R, Stoiber H, Dierich MP. Complement. In: Paul WE (ed.), Fundamental Immunology. Philadelphia: Lippincott-Raven Publishers, 2003: 1077-103.
5. Ellis M. Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Mol Immunol 2001; 38: 947-57.
6. Würzner R. Complement and infectious diseases. Contrib Microbiol 2003; 10: 1-17.
7. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803
8. Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994; 19 (Suppl. 1): S41-8.
9. Kozel TR, Wilson MA, Farrell TP, Levitz SM. Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae. Infect Immun 1989; 57: 3412-7.
10. Sturtevant JE, Latgé JP. Interactions between conidia of Aspergillus fumigatus and human complement component C3. Infect Immun 1992; 60: 1913-8.
11. Sturtevant J, Latgé JP. Participation of complement in the phagocytosis of the conidia of Aspergillus fumigatus by human polymorphonuclear cells. J Infect Dis 1992; 166: 580-6.
12. Henwick S, Hetherington SV, Patrick CC. Complement binding to Aspergillus conidia correlates with pathogenicity. J Lab Clin Med 1993; 122: 27-35.
13. Hector RF, Yee E, Collins MS. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis. Infect Immun 1990; 58: 1476-8.
14. Levitz SM. Overview of host defences in fungal infections. Clin Infect Dis 1992; 14(Suppl. 1): S37-42.
15. Laxalt KA, Kozel TR. Chemotarigenesis and activation of the alternative complement pathway by encapsulated and nonencapsulated Cryptococcus neoformans. Infect Immun 1979; 26: 435-40.
16. Waldorf AR, Diamond RD. Neutrophil chemotactic responses induced by fresh and swollen Rhizopus oryzae spores and Aspergillus fumigatus conidia. Infect Immun 1985; 48: 458-63.
17. Ember JA, Jagels MA, Hugli TE. Characterization of complement anaphylatoxins and their biological responses. In: Volanakis JE, Frank MM (eds), The Human Complement System in Health and Disease. New York: Dekker, M. (Inc.), 1998: 241-84.
18. Ames RS, Li Y, Sarau HM et al. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 1996; 271: 20231-4.
19. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991; 349: 614-7.
20. desArg enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol 2000; 166: 3410-5.
21. Daniels RH, Houston WA, Petersen MM, Williams JD, Williams BD, Morgan BP. Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack. Immunology 1990; 69: 237-42.
22. Schonermark M, Deppisch R, Riedasch G, Rother K, Mansch GM. Induction of mediator release from human glomerular mesangial cells by the terminal complement components C5b-9. Int Arch Allergy Appl Immunol 1991; 96: 331-7.
23. Tsai HF, Chang YC, Washburn RG, Wheeler MH, Kwon-Chung KJ. The developmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence. J Bacteriol 1998; 180: 3031-8.
24. Tsai HF, Washburn RG, Chang YC, Kwon-Chung KJ. Aspergillus fumigatus arp1 modulates conidial pigmentation and complement deposition. Mol Microbiol 1997; 26: 175-84.
25. Washburn RG, Hammer CH, Bennett JE. Inhibition of complement by culture supernatants of Aspergillus fumigatus. J Infect Dis 1986; 154: 944-51.
26. Washburn RG, DeHart DJ, Agwu DE, Bryant-Varela BJ, Julian NC. Aspergillus fumigatus complement inhibitor: production, characterization and purification by hydrophobic interaction and thin-layer chromatography. Infect Immun 1990; 58: 3508-15.
27. Tomee JFC, Kauffman HF. Putative virulence factors of Aspergillus fumigatus. Clin Exp Allergy 2000; 30: 476-84.
28. Morgan BP, Gasque P. Expression of complement in the brain: role in health and disease. Immunol Today 1996; 17: 461-6.
29. Speth C, Dierich MP, Gasque P. Neuroinvasion by pathogens: a key role of the complement system. Mol Immunol 2002; 38: 669-79.
30. Odds FC. Candida and Candidosis, 2nd edn. London: Baillière Tindall, 1988.
31. Eisenstein BI. New opportunistic infections - more opportunities. N Engl J Med 1990; 323: 1625-7.
32. Fidel PL. Jr Immunity to Candida. Oral Dis 2002; 8(Suppl. 2): 69-75.
33. Yamamura M, Valdimarsson H. Participation of C3 in intracellular killing of Candida albicans. Scand J Immunol 1977; 6: 591-4.
34. Morelli R, Rosenberg LT. The role of complement in the phagocytosis of Candida albicans by mouse peripheral blood leukocytes. J Immunol 1971; 107: 476-80.
35. Kozel T. Activation of the complement system by pathogenic fungi. Clin Microbiol Rev 1996; 9: 34-46.
36. Ray TL, Wuepper KD. Activation of the alternative (properdin) pathway of complement by Candida albicans and related species. J Invest Dermatol 1976; 67: 700-3.
37. Thong YH, Ferrante A. Alternative pathway of complement activation by Candida albicans. Aust N Z J Med 1978; 8: 620-2.
38. Kozel TR, Weinhold LC, Lupan DM. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect Immun 1996; 64: 3360-8.
39. Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect Immun 1995; 63: 2714-9.
40. Diamond RD, Haudenschild CC. Monocyte-mediated serum-independent damage to hyphal and pseudohyphal forms of Candida albicans in vitro. J Clin Invest 1981; 67: 173-82.
41. Gruber A, Lukasser-Vogl E, von Zepelin MB, Dierich MP, Würzner R. Human immunodeficiency virus type 1 gp160/gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J Infect Dis 1998; 177: 1057-63.
42. Triebel T, Grillhösl B, Kacani L et al. Importance of the terminal complement components for immune defence against Candida. Int J Med Microbiol 2003; 292: 527-36.
43. Gelfand JA, Hurley DL, Fauci AS, Frank MM. Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis 1978; 138: 9-16.
44. Fulurija A, Ashman RB, Papadimitriou JM. Early inflammatory responses to Candida albicans infection in inbred and complement-deficient mice. FEMS Immunol Med Microbiol 1996; 14: 83-94.
45. Wilson BD, Sohnle PG. Neutrophil accumulation and cutaneous responses in experimental cutaneous candidiasis of genetically complement-deficient mice. Clin Immunol Immunopathol 1988; 46: 284-93.
46. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991: 4: 359-95.
47. Diamond RD, Oppenheim F, Nakagawa Y, Krzesicki R, Haudenschild CC. Properties of a product of Candida albicans hyphae and pseudohyphae that inhibits contact between the fungi and human neutrophils in vitro. J Immunol 1980; 125: 2797-804.
48. Kaminishi H, Miyaguchi H, Tamaki T et al. Degradation of humoral host defense by Candida albicans proteinase. Infect Immun 1995; 63: 984-8.
49. Calderone RA, Linehan L, Wadsworth E, Sandberg AL. Identification of C3d receptors on Candida albicans. Infect Immun 1988; 56: 252-8.
50. Heidenreich F, Dierich MP. Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun 1985; 50: 598-600.
51. Edwards JE, Gaither TA, O'Shea JJ et al. Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol 1986; 137: 3577-83.
52. Gilmore BJ, Retsinas EM, Lorenz JS, Hostetter MK. An iC3b receptor on Candida albicans: structure, function, and correlates for pathogenicity. J Infect Dis 1988; 157: 38-46.
53. Eigentler A, Schulz TF, Larcher C et al. C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun 1989; 57: 616-22.
54. Alaei S, Larcher C, Ebenbichler C, Prodinger WM, Janatova J, Dierich MP. Isolation and biochemical characterization of the iC3b receptor of Candida albicans. Infect Immun 1993; 61: 1395-9.
55. Gale C, Finkel D, Tao N et al. Cloning and expression of a gene encoding an integrin-like protein in Candida albicans. Proc Natl Acad Sci USA 1996; 93: 357-61.
56. Bernhardt J, Herman D, Sheridan M, Calderone R. Adherence and invasion studies of Candida albicans strains, using in vitro models of esophageal candidiasis. J Infect Dis 2001; 184: 1170-5.
57. Würzner R, Langgartner M, Spötl L et al. Temperature-dependent surface expression of the β2-integrin analogue of Candida albicans and its role in adhesion to the human endothelium. Exp Clin Immunogenet 1996; 13: 162-73.
58. Moors MA, Stull TL, Blank KJ, Buckley HR, Mosser DM. A role for complement receptor-like molecules in iron acquisition by Candida albicans. J Exp Med 1992; 175: 1643-51.
59. Gale CA, Bendel CM, McClellan M et al. Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. Science 1998; 279: 1355-8.
60. Würzner R, Gruber A, Stoiber H et al. Human immunodeficiency virus type 1 gp41 binds to Candida albicans via complement C3-like regions. J Infect Dis 1997; 176: 492-8.
61. Würzner R. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol Immunol 1999; 36: 249-60.
62. Meri T, Hartmann A, Lenk D et al. The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun 2002; 70: 5185-92.
63. Good CB, Coax WA. Cryptococcal infection in patients with AIDS. N Engl J Med 1990; 322: 243-7.
64. Young BJ, Kozel TR. Effects of strain variation, serotype and structural modification on the kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect Immun 1993; 61: 2966-72.
65. Kozel TR, Tabuni A, Young BJ, Levitz SM. Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells. Infect Immun 1996; 64: 2336-8.
66. Kozel TR. Complement activation by pathogenic fungi. Res Immunol 1998; 149: 309-20.
67. Blackstock R, Murphy JW. Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cyrptococcus neoformans. Infect Immun 1997; 65: 4114-21.
68. Davies SF, Clifford DP, Hoidal JR, Repine JE. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. J Infect Dis 1982; 145: 870-4.
69. Levitz SM, Tabuni A. Binding of Cryptococcus neoformans by human cultured macrophages: requirements for multiple complement receptors and actin. J Clin Invest 1991; 687: 528-35.
70. Levitz SM, Tabuni A, Kozel TR, MacGill RS, Ingalls RR, Golenbock DT. Binding of Cryptococcus neoformans to heterologously expressed human complement receptors. Infect Immun 1997; 65: 931-5.
71. Vecchierelli A, Retini C, Casadevall A, Monari C, Pietrella D, Kozel TR. Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans. Infect Immun 1998; 66: 4324-30.
72. Matsushima K, Oppenheim JJ. Interleukin-8 and MCAF: novel inflammatory cytokines inducible by IL-1 and TNF. Cytokine 1989; 1: 2-13.
73. Liles WC, Van Hoorhis WC. Nomenclature and biological significance of cytokines involved in inflammation and the last immune response. J Infect Dis 1995; 172: 1573-80.
74. Monari C, Casadevall A, Pietrella D, Bistoni F, Vecchiarelli A. Neutrophils from patients with advanced human immunodeficiency virus infection have impaired complement receptor function and reserved Fcγ receptor function. J Infect Dis 1999; 180: 1542-9.
75. Delfino D, Cianci L, Migliardo M et al. Tumor necrosis factor-inducing activities of Cryptococcus neoformans components. Infect Immun 1996; 64: 5199-204.
76. Levitz SM, Tabuni A, Kornfeld H, Reardon CC, Golenbock DT. Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect Immun 1994; 62: 1975-81.
77. Cross CE, Collins HL, Bancroft GJ. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans. Immunology 1997; 91: 289-96.
78. Dong ZM, Murphy JW. Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun 1997; 65: 557-63.
79. Monari C, Kozel TR, Bistoni F, Vecchiarelli A. Modulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans. Infect Immun 2002; 70: 3363-70.
80. Mackinnon JM. On the importance of South American blastomycosis. Mycopathologia 1970; 41: 187-93.
81. Borges-Walmsley MI, Chen D, Shu X, Walmsley AR. The pathobiology of Paracoccidioides brasiliensis. Trends Microbiol 2002; 10: 80-7.
82. Calich VL, Kipnis TL, Mariano M, Neto CF, Da Silva WD. The activation of the complement system by Paracoccidioides brasiliensis in vitro: its opsonlc effect and possible significance for an in vivo model of infection. Clin Immunol Immunopathol 1979; 12: 21-30.
83. Munk ME, Kajdacsy-Balla A, Del Negro G, Cuce LC, Da Silva WD. Activation of human complement system in paracoccidioidomycosis. J Med Vet Mycol 1992; 30: 317-21.
84. De Messias IT, Mohren D. Classical and alternative complement pathway activation in paracoccidioidomycosis. J Invest Allergol Clin Immunol 1994; 4: 91-5.
85. Crott LS, Valim YM, Silva CL, Barbosa JE. The role of the complement system in the neutrophil functions stimulated in vitro by an alkali-insoluble cell wall fraction of Paracoccidioides brasiliensis. J Med Vet Mycol 1993; 31: 17-27.
86. Crott LSP, Lucisano-Valim YM, Silva CL, Barbosa JE. Interactions of F1 fractions from different strains of Paracoccidioides brasiliensis with human complement and with human neutrophils. Mycopathologia 1997; 140: 19-27.
87. De Messias IJ, Reis A, Brenden M, Queiroz-Telles F, Mauff G. Association of major histocompatibility complex class III complement components C2, BF and C4 with Brazilian paracoccidioidomycosis. Complement Inflamm 1991; 8: 288-93.
88. Teixeira JE, Martinez R, Camara LM, Barbosa JE. Expression of complement receptor type 1 (CR1) on erythrocytes of paracoccidiodomycosis patients. Mycopathologia 2001; 152: 125-33.
89. Chequer-Bou-Habib D, Oliveira-Neto MP, Ferreira-da-Cruz MF, Galvao-Castro B. The possible role of circulating immune complexes in the deficiency of cell-mediated immunity in paracoccidioidomycosis. Braz J Med Biol Res 1989; 22: 205-12.
90. Cosio FG, Shen XP, Birmingham DJ, Van Aman M, Hebert LA. Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol 1990; 145: 4198-206.
91. Nardin A, Lindorfer MA, Taylor RP. How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells? Mol Immunol 1999; 36: 827-35.
92. Mold C, Gurulé C, Otero D, Du Clos TW. Complement-dependent binding of C-reactive protein complexes to human erythrocyte CR1. Clin Immunol Immunopathol 1996; 81: 153-60.
93. Zhang MX, Klein B. Activation, binding and processing of complement component 3 (C3) by Blastomyces dermatitidis. Infect Immun 1997; 65: 1849-55.
94. Zhang MX, Brandhorst TT, Kozel TR, Klein BS. Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast. Infect Immun 2001; 69: 7559-64.
95. Newman SL, Chaturvedi S, Klein BS. The WI-1 antigen of Blastomyces dermatitidis yeasts mediates binding to human macrophage CD11b/CD18 (CR3) and CD14. J Immunol 1995; 154: 753-61.
96. Bullock WE, Wright SD. Role of the adherence-promoting receptors, CR3, LFA-1, and p150,95, in binding of Histoplasma capsulatum by human macrophages. J Exp Med 1987; 165: 195-210.
97. Ignatov A, Keath EJ. Molecular cell biology and molecular genetics of Histoplasma capsulatum. Int J Med Microbiol 2002; 292: 349-61.
98. Long KH, Gomez FJ, Morris RE, Newman SL. Identification of heat shock protein 60 as the ligand on Histoplasma capsulatum that mediates binding to CD18 receptors on human macrophages. J Immunol 2003; 170: 487-94.
99. Marth T, Kelsall BL. Regulation of interleukin-12 by complement receptor 3 signaling. J Exp Med 1997; 185: 1987-95.